IPO Year: 2020
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/27/2026 | $20.00 | Overweight | Piper Sandler |
| 2/26/2026 | Overweight | Cantor Fitzgerald | |
| 2/19/2026 | $10.00 | Neutral → Outperform | Mizuho |
DEFA14A - LeonaBio, Inc. (0001620463) (Filer)
DEF 14A - LeonaBio, Inc. (0001620463) (Filer)
SCHEDULE 13D/A - LeonaBio, Inc. (0001620463) (Subject)
10-Q - LeonaBio, Inc. (0001620463) (Filer)
8-K - LeonaBio, Inc. (0001620463) (Filer)
EFFECT - LeonaBio, Inc. (0001620463) (Filer)
EFFECT - LeonaBio, Inc. (0001620463) (Filer)
424B3 - LeonaBio, Inc. (0001620463) (Filer)
424B3 - LeonaBio, Inc. (0001620463) (Filer)
S-8 - LeonaBio, Inc. (0001620463) (Filer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - LeonaBio, Inc. (0001620463) (Issuer)
4 - LeonaBio, Inc. (0001620463) (Issuer)
4 - LeonaBio, Inc. (0001620463) (Issuer)
3 - LeonaBio, Inc. (0001620463) (Issuer)
3 - LeonaBio, Inc. (0001620463) (Issuer)
3 - LeonaBio, Inc. (0001620463) (Issuer)
4 - LeonaBio, Inc. (0001620463) (Issuer)
4 - LeonaBio, Inc. (0001620463) (Issuer)
4 - LeonaBio, Inc. (0001620463) (Issuer)
4 - LeonaBio, Inc. (0001620463) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Piper Sandler initiated coverage of LeonaBio with a rating of Overweight and set a new price target of $20.00
Cantor Fitzgerald initiated coverage of LeonaBio with a rating of Overweight
Mizuho upgraded LeonaBio from Neutral to Outperform and set a new price target of $10.00
Fastest customizable press release news feed in the world
BOTHELL, Wash., May 27, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ:LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced that it will participate in the 5th Annual ALS Drug Development Summit, taking place June 2-4, 2026 in Boston, MA, and the BIO International Convention, taking place June 22-25, 2026 in San Diego, CA. Details are as follows: 5th Annual ALS Drug Development Summit Oral Presentation Title: Advancing ATH-1105 in ALS: Strategic Trial Design, Biomarker Integration & Adaptive MethodologiesSession Title: Redefining Biomarkers and Trial Design to Accelerate Neurodeg
Advancing Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator, a Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations Expects to Complete Enrollment of Phase 3 Clinical Trial of Lasofoxifene in Treatment-Resistant ER-positive, HER2-negative, ESR1-mutated Metastatic Breast Cancer in 4Q 2026 with Topline Data Anticipated in 2H 2027 On-track to Initiate Phase 2 Proof-of-Concept Study of ATH-1105 in ALS patients in 2H 2026 Recent Events Include Three Appointments to Board of Directors and Virtual Key Opinion Leader Event Highlighting Potential of Lasofoxifene BOTHELL, Wash., May 07, 2026 (GLOBE NEWSWIRE) -- Leon
BOTHELL, Wash., May 07, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ:LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced the appointment of Fred Callori, J.D., Natalie Holles, and Peter B. Silverman, J.D. to its Board of Directors, effective as of May 5, 2026. The company also announced that John Fluke, Jr., who has served on the Board of Directors since 2014, retired effective May 4, 2026. "We are delighted to welcome Fred, Natalie, and Peter to LeonaBio's Board of Directors," said Mark Litton, Ph.D., President and Chief Executive Officer of LeonaBio. "Collectively, they bring
Management to be Joined by Two Clinical Leaders in the Breast Cancer Field Expected to Complete Enrollment in Ongoing ELAINE-3 Phase 3 Registrational Study of Lasofoxifene in Metastatic Breast Cancer in 4Q26 with Data Expected in 2H27 Webinar Event on Wednesday, April 29, 2026, at 12:00 p.m. ET BOTHELL, Wash., April 23, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ:LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced that it will host a virtual Key Opinion Leader event with two leading physician experts in the breast cancer field to discuss the current and evolving treatment la
BOTHELL, Wash., April 21, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ:LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, attended the American Association for Cancer Research Annual Meeting 2026 (AACR26), where independent researchers at Virginia Commonwealth University's Massey Comprehensive Cancer Center presented nonclinical data on lasofoxifene, including its potential for a bone protective role in metastatic breast cancer.1 "We are delighted to learn the findings of this independent research at AACR26, attended by an audience of the world's leading oncology researchers. We believe these
Acquired License to Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator (SERM), a Potential Multi-Billion Dollar Opportunity as Treatment Option for Breast Cancer Patients with ESR1-Mutations Received Gross Proceeds of $90 Million in Private Placement Financing of Common Stock and Warrants with Cash-Exercisable Warrants Potentially Providing up to an Additional $146 Million to Support Development of Lasofoxifene Through Key Clinical and Regulatory Milestones Expect to Complete Enrollment of Phase 3 Clinical Trial of Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer in 4Q 2026 with Topline Data Anticipated in 2H 2027
BOTHELL, Wash., Feb. 03, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ:LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced the appointment of Mark F. Kubik as Chief Business Officer. In this role, Mr. Kubik will lead LeonaBio's business development strategy and execution, with responsibility for licensing, partnership strategy, and corporate development initiatives. Mr. Kubik previously served as a strategic consultant to LeonaBio, where he played an instrumental role in the transformational transaction announced in December 2025, in which LeonaBio acquired rights to the Phase 3
Live Leadership Updates
Advancing Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator, a Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations Expects to Complete Enrollment of Phase 3 Clinical Trial of Lasofoxifene in Treatment-Resistant ER-positive, HER2-negative, ESR1-mutated Metastatic Breast Cancer in 4Q 2026 with Topline Data Anticipated in 2H 2027 On-track to Initiate Phase 2 Proof-of-Concept Study of ATH-1105 in ALS patients in 2H 2026 Recent Events Include Three Appointments to Board of Directors and Virtual Key Opinion Leader Event Highlighting Potential of Lasofoxifene BOTHELL, Wash., May 07, 2026 (GLOBE NEWSWIRE) -- Leon
BOTHELL, Wash., May 07, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ:LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced the appointment of Fred Callori, J.D., Natalie Holles, and Peter B. Silverman, J.D. to its Board of Directors, effective as of May 5, 2026. The company also announced that John Fluke, Jr., who has served on the Board of Directors since 2014, retired effective May 4, 2026. "We are delighted to welcome Fred, Natalie, and Peter to LeonaBio's Board of Directors," said Mark Litton, Ph.D., President and Chief Executive Officer of LeonaBio. "Collectively, they bring
BOTHELL, Wash., Feb. 03, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ:LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced the appointment of Mark F. Kubik as Chief Business Officer. In this role, Mr. Kubik will lead LeonaBio's business development strategy and execution, with responsibility for licensing, partnership strategy, and corporate development initiatives. Mr. Kubik previously served as a strategic consultant to LeonaBio, where he played an instrumental role in the transformational transaction announced in December 2025, in which LeonaBio acquired rights to the Phase 3